NCT05848843View on ClinicalTrials.gov

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 25, 2023

Primary Completion Date

January 16, 2024

Study Completion Date

January 16, 2024

Conditions
Lung CancerGastro-intestinal Cancer
Interventions
DRUG

Durvalumab

Given by vein (IV)

DRUG

Adagrasib

Given by PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Mirati Therapeutics Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05848843 - A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Biotech Hunter | Biotech Hunter